- Rational and evolutionary optimization of aaRS–tRNA recognition
- Fine control over codon reassignment efficiency
- Quantitative comparison of orthogonal translation performance
The GCEngine™ platform is a modular genetic code expansion (GCE) platform built around orthogonal translation engineering. By integrating tRNA display–based discovery, orthogonal aaRS/tRNA system development, and quantitative ncAA validation, the platform enables precise and programmable incorporation of non-canonical amino acids (ncAAs) across in vitro and in vivo systems.
GCEngine™ is aptRNA's proprietary GCE platform, purpose-built to support rigorous, data-driven engineering of orthogonal translation systems.
Genetic code expansion is a technology that reprograms the translation machinery to incorporate amino acids beyond the canonical twenty. This is achieved by introducing orthogonal aminoacyl-tRNA synthetase (aaRS)/tRNA pairs that decode reassigned codons—most commonly the amber stop codon (UAG)—while remaining functionally separate from endogenous translation.
By decoupling ncAA incorporation from host amino acid pools, GCE enables site-specific installation of chemical functionalities that are inaccessible to natural biosynthesis, forming the basis for advanced protein engineering.
Fig.1 Diagram of Genetic Code Expansion. (Kim, S., et al., 2022)
At the core of GCEngine™ lies a tRNA display–based discovery and optimization strategy. This approach treats tRNA not merely as a decoding adaptor, but as an engineerable molecular scaffold whose sequence, structure, modification state, and interaction surfaces can be systematically explored. Through tRNA display and library-driven screening, GCEngine™ enables:
This technology underpins the platform's ability to generate robust, host-compatible orthogonal systems.
The scientific output of GCEngine™ is a set of validated orthogonal aaRS/tRNA pairs that function as modular translation units. Each unit can be reused across multiple protein targets and host systems for its cognate ncAA, and new units can be added as additional ncAAs are brought under control.
Crucially, orthogonality is designed to ensure:
This modularity underpins the scalability and transferability of the platform.
The GCEngine™ platform implements a closed-loop workflow that connects molecular design, experimental validation, and biological integration:
 |
 |
 |
| Orthogonal tRNA/aaRS Pair Identification | ncAA Incorporation – In Vitro Validation | ncAA Incorporation – In Vivo Applications |
| Structure-guided design, library construction, screening, and directed evolution are used to identify aaRS/tRNA pairs that are orthogonal to host translation and specific for target ncAAs. | Cell-free translation and aminoacylation assays quantify charging kinetics, decoding fidelity, and ncAA incorporation efficiency. Reporter systems and LC–MS/MS analyses verify site-specific insertion at the intended codon positions. | Optimized systems are transferred into E. coli, yeast, or mammalian cells. Expression balance, codon reassignment efficiency, and ncAA dependency are tuned for reliable cellular translation in the chosen host. |
With validated orthogonal translation systems in place, the GCEngine™ platform enables precise chemical control over proteins across multiple application domains. By combining engineered aaRS/tRNA pairs with ncAA incorporation, the platform supports applications ranging from therapeutic protein development to synthetic biological circuits and molecular diagnostics.
 |
Pharmaceutical R&D | GCEngine™ enables site-specific ncAA incorporation in therapeutic
peptides, proteins, antibodies, and cytokines. Applications span cancer, autoimmune and inflammatory diseases, and infectious diseases & vaccines, supporting ncAA-based functionalization, epitope optimization, and improved stability for next-generation biologics. |
 |
Synthetic Biology | GCEngine™ expands synthetic biology by enabling diverse ncAA incorporation modes, including chemically reactive, photo-crosslinking, stability-enhancing, click-compatible, cyclic, and small polar ncAAs. These capabilities support programmable translation, orthogonal control, and ncAA-based in vitro translation systems, enabling modular circuit design and expanded chemical functionality beyond the natural genetic code. |
 |
Diagnostics & Biosensing | GCEngine™ supports ncAA-incorporated peptide and protein sensors with enhanced specificity and tunable signal output. Site-specific installation of reporter groups or reactive handles enables translation-coupled sensing and orthogonal detection strategies for diagnostic and analytical applications. |
The GCEngine™ platform provides a structured path from genetic code expansion theory to practical orthogonal translation systems. Whether your work focuses on fundamental translation research or advanced protein engineering, the GCEngine™ platform offers the scientific depth and engineering rigor needed to redesign translation with precision. Contact us to explore how the GCEngine™ platform can support your ncAA and orthogonal translation projects.
All our services are exclusively intended for preclinical research purposes. They are not intended for diagnostic, therapeutic, or patient management applications.
A specialized platform advancing genetic code expansion through orthogonal tRNA/aaRS technologies, enabling precise ncAA incorporation for biotherapeutic development, synthetic biology, and diagnostics.